Upregulated LMO1 in prostate cancer acts as a novel coactivator of the androgen receptor
Upregulated LMO1 in prostate cancer acts as a novel coactivator of the androgen receptor
复制标题
前列腺癌中上调的 LMO1 作为雄激素受体的新型共激活剂
DOI：
10.3892/ijo.2015.3195
复制
发表时间：
2015-12-01
影响因子：
5.2
通讯作者：
Li, Feng
中科院分区：
文献类型：
--
作者：
Gu, Hui;Liu, Tong;Li, Feng
LMO1是一种核转录辅助调节因子，与T细胞急性淋巴细胞白血病和神经母细胞瘤的发病有关。然而，LMO1在人类前列腺癌(PCa)中的作用尚不清楚。雄激素受体(AR)在前列腺癌的发生发展中起重要作用。AR信号通路的激活可能受AR辅因子的调节。在本研究中，我们发现LMO1可以与AR结合，并与AR在细胞核内共同定位。此外，LMO1在前列腺癌组织中的表达显著高于良性前列腺增生症(BPH)组织。此外，LMO1似乎是一种新的辅助激活因子，可以增强AR的转录活性，随后上调AR下游靶P21和PSA的表达。综上所述，LMO1似乎是参与前列腺癌进展的AR的辅助激活因子，并可能成为治疗前列腺癌的一个有前途的分子靶点。
LMO1, a nuclear transcription coregulator, is implicated in the pathogenesis of T-cell acute lymphoblastic leukemia and neuroblastoma. However, the role of LMO1 in human prostate cancer (PCa) is still unknown. Androgen receptor (AR) plays a critical role in the progression of prostate cancer. The activation of AR signaling pathway could be modulated by AR cofactors. In the present study, we discovered that LMO1 could bind to AR and co-localize with AR in the nucleus. In addition, the expression of LMO1 in human PCa tissues was significantly higher than that in benign prostate hyperplasia (BPH) tissues. Moreover, LMO1 appeared to be a novel coactivator to enhance AR transcriptional activities, followed by the elevation of expression of P21 and PSA, downstream targets of AR. Taken together, LMO1 appears to be a coactivator of AR involved in the progression of prostate cancer, and could be a promising molecular target for treating prostate cancer.